ERAS · Erasca, Inc.
Market Cap
$6.31B
Shares
349.76M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.03
Open$19.25
Day$18.00–19.59
52W close$1.43–22.47
Avg vol 30d3.3M
Short int30.8M · 8.8% float · 10.0d
Short vol68%
Last earningsMay 8, 2024
DataJul 2021–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
−0%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
79%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+14%
trailing
YTD return
+385%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +62 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.82% of float · ▲ +3.0% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
258 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
+36%
Y/Y
Free cash flow
$-95.6M
Quant / Vol
risk profile
Volatility
104%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
−0%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
79%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $18 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +62 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.82% of float · ▲ +3.0% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
258 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $18 · 79%
Range high $22
vs 200-day avg +44%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents and marketable securities | $341.8M | year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERAS
this stock
Erasca, Inc.
|
$6.31B | +384.7% | — | — | 8.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERAS | +2.3% | -0.7% | +14.4% | -0.7% | +384.7% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +1.8% | -3.7% | +1.0% | -3.7% | +371.9% |
Key facts
CIK
1761918
CUSIP
29479A108
13F (30d)
225 filings
223 filers
Visit website
Investor relations